Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3408278 | 0.83 | LMNA (0.46) | HTR2ASLC6A2HRH1L3MBTL1LMNA | |
| SCHEMBL27389987 | 0.83 | LMNA (0.46) | HTR2ASLC6A2HRH1L3MBTL1LMNA | |
| SCHEMBL2911081 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA4TAAR1HTR2ANOS2 | |
| SCHEMBL5831230 | 0.79 | GSR (0.50) | L3MBTL1LMNA | |
| SCHEMBL28768889 | 0.79 | L3MBTL1 (0.44) | L3MBTL1LMNA | |
| SCHEMBL23868114 | 0.79 | GSR (0.50) | L3MBTL1LMNA | |
| SCHEMBL10986680 | 0.79 | L3MBTL1 (0.40) | HTR2ASLC6A2HRH1L3MBTL1LMNA | |
| SCHEMBL1609920 | 0.79 | L3MBTL1 (0.40) | HTR2ASLC6A2HRH1L3MBTL1LMNA | |
| SCHEMBL21625269 | 0.79 | CASR (0.44) | SLC6A2L3MBTL1LMNA | |
| SCHEMBL913620 | 0.78 | TAAR1 (0.52) | CHRNB2CHRNA4TAAR1HTR2ANOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143824-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2013-06-06 | — | — | US | claimed |
| US-20120058953-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20110039324-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2011-02-17 | — | — | US | claimed |
| US-20090148921-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. (US) | 2009-06-11 | — | — | US | claimed |
| EP-1590666-B1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2008-07-09 | — | — | EP | claimed |
| EP-1590666-A4 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2006-07-26 | — | — | EP | claimed |
| EP-1590666-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | Genentech, Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| US-20040171554-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004072641-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2004-08-26 | — | — | WO | claimed |
| WO-2013089689-A1 | CONSTITUENT OF DESMODIUM ELEGANS AND METHODS OF USE | KNELLER BRUCE W (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8324221-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110039324-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2220100-A2 | CHIRAL CYCLOPLATINIZED COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINE AND CATALYSTS | Rheinisch-Westfälisch-Technische Hochschule Aachen (DE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009077462-A2 | CHIRAL CYCLOPLATINIZED COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINE AND CATALYSTS | Rheinisch-Westfälische Technische Hochschule Aachen (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-1590666-B1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, PIK3CA | CHRNB2 4868/4885CHRNA4 4880/4885TAAR1 4116/4885 |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, AKT2 | CHRNB2 4871/4885CHRNA4 4878/4885TAAR1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.